PAFSC in Japan endorses lecanemab for slowing the progression of mild cognitive impairment due to Alzheimer's disease.-Eisai
Eisai’s lecanemab gained the recommendation of the Pharmaceutical Affairs and Food Sanitation Council’s (PAFSC) First Committee on Drugs on August 21, setting the stage for its regulatory approval soon as Japan’s first Alzheimer’s disease (AD)-modifying therapy.
Emphasis will now shift to its pricing and reimbursement. Lecanemab is an anti-amyloid beta (Abeta) protofibril antibody jointly developed with US partner Biogen. The PAFSC First Committee on Drugs, endorsed the product for slowing the progression of mild cognitive impairment (MCI) due to AD and mild AD dementia, collectively called “early AD.”
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.